Systemic Lupus Erythematosus (SLE)
116
49
57
27
Key Insights
Highlights
Success Rate
84% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
4.3%
5 terminated out of 116 trials
84.4%
-2.2% vs benchmark
10%
12 trials in Phase 3/4
37%
10 of 27 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 27 completed trials
Clinical Trials (116)
SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus
Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires
Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus
An Extension Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus
C-CAR168 CAR T-Cell Therapy for the Treatment of Lupus Nephritis Refractory to Standard Therapy
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of VIS171 in Participants With Autoimmune Disease(s)
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases
INTERSTELLAR - International Study Evaluating Lupus Outcomes After Anifrolumab Real World Use
Modeling the Early Stages of Autoimmunity Through the Study of Immunological Thrombocytopenic Purpura and Juvenile Lupus
Study on Early Visual Dysfunction in Patients With Systemic Lupus Erythematosus
An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE).
Universal Anti-CD70 CAR-T (CHT101) Cell Therapy for Relapsed Refractory Systemic Lupus Erythematosus
Periodontal Disease in Rare Renal Disorders (PERIO-RA-RE)
3TR (Taxonomy, Treatment, Targets and Remission) Systemic Lupus Erythematosus Study Protocol 2
3TR (Taxonomy, Treatment, Targets and Remission) Systemic Lupus Erithematosus Study Protocol
CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus
COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
AZAHAR Study To Describe Anifrolumab in a Real-World Setting